Inno-Gene S.A. provides genetic diagnostic solutions in Poland. More Details
+ 1 more risk
Adequate balance sheet with poor track record.
Share Price & News
How has Inno-Gene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IGN's share price has been volatile over the past 3 months.
7 Day Return
PL Life Sciences
1 Year Return
PL Life Sciences
Return vs Industry: IGN exceeded the Polish Life Sciences industry which returned 68.1% over the past year.
Return vs Market: IGN exceeded the Polish Market which returned -13% over the past year.
Price Volatility Vs. Market
How volatile is Inno-Gene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StInno-Gene S.A.'s (WSE:IGN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
4 months ago | Simply Wall StCan We See Significant Insider Ownership On The Inno-Gene S.A. (WSE:IGN) Share Register?
6 months ago | Simply Wall StDid You Miss Inno-Gene's (WSE:IGN) Impressive 155% Share Price Gain?
Is Inno-Gene undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IGN is poor value based on its PE Ratio (444.2x) compared to the XE Life Sciences industry average (60.6x).
PE vs Market: IGN is poor value based on its PE Ratio (444.2x) compared to the Polish market (12.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IGN is overvalued based on its PB Ratio (31.8x) compared to the XE Life Sciences industry average (5.6x).
How is Inno-Gene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Inno-Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Inno-Gene's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Inno-Gene competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Inno-Gene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IGN has a large one-off gain of PLN56.5K impacting its June 30 2020 financial results.
Growing Profit Margin: IGN's current net profit margins (12.2%) are lower than last year (27.1%).
Past Earnings Growth Analysis
Earnings Trend: IGN has become profitable over the past 5 years, growing earnings by 18.4% per year.
Accelerating Growth: IGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IGN had negative earnings growth (-67.6%) over the past year, making it difficult to compare to the Life Sciences industry average (19.3%).
Return on Equity
High ROE: IGN's Return on Equity (2.9%) is considered low.
How is Inno-Gene's financial position?
Financial Position Analysis
Short Term Liabilities: IGN's short term assets (PLN3.3M) do not cover its short term liabilities (PLN13.8M).
Long Term Liabilities: IGN's short term assets (PLN3.3M) exceed its long term liabilities (PLN285.4K).
Debt to Equity History and Analysis
Debt Level: IGN's debt to equity ratio (27.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if IGN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: IGN's debt is well covered by operating cash flow (61.7%).
Interest Coverage: IGN's interest payments on its debt are well covered by EBIT (20.4x coverage).
What is Inno-Gene current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IGN's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Jacek Wojciechowicz serves as President and R&D Director at Centrum Badan DNA Sp. z o.o. Mr. Wojciechowicz serves as the President of the Management Board at Inno-Gene S.A.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Inno-Gene S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Inno-Gene S.A.
- Ticker: IGN
- Exchange: WSE
- Founded: 2006
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł92.643m
- Shares outstanding: 5.70m
- Website: https://www.inno-gene.pl
Number of Employees
- Inno-Gene S.A.
- Poznan Science and Technology Park
- 46 Rubiez str.
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IGN||WSE (Warsaw Stock Exchange)||Yes||Common Bearer Shares||PL||PLN||Feb 2011|
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It engages in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/18 04:15|
|End of Day Share Price||2020/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.